日本語 EN 中文

2026.06.22

Commencement of Partnership to Globally Expand AI Medical Devices Supporting Personalized Asthma Treatment: Advancing Personalized Medicine to Bridge Healthcare Disparities through Machine Learning Based on Patient-Reported Outcomes (PRO)

Overview


Yamaguchi University and Nozomi MedAlliance Co., Ltd. have launched a collaborative initiative aimed at the global expansion of an AI-driven Software as a Medical Device (SaMD) designed to provide optimal personalized treatment for asthma patients.

This project has been selected for the “Medical Device Research and Development Promotion Program (Challenge Type)” by the Japan Agency for Medical Research and Development (AMED). By leveraging proprietary machine learning technology based on Patient-Reported Outcomes (PRO), the initiative aims to deliver advanced personalized medicine even to regions such as low- and middle-income countries (LMICs) that lack specialized diagnostic equipment and medical specialists. Through this effort, the partnership seeks to bridge global healthcare disparities and promote the widespread adoption of digital health technologies.

RICeD Member
  • Division of Systems Medicine and Informatics
  • 　　　Kazuki Hamada（Respirology）
  • 　　　Yoshiyuki Asai（Systems Bioinformatics）　
Project Initiatives
  • 　
  • This initiative will focus on driving the following three key areas:
  • ・Development of a Prototype: Building upon the developed machine learning algorithms to create a personalized treatment support AI software program.
  • ・Verification of Clinical Utility: Leveraging a longitudinal observational research database, Yamaguchi University will statistically demonstrate the efficacy of the treatment strategies recommended by the AI.
  • ・Establishment of a Business Infrastructure for Global Expansion: By integrating the technology developed and verified by Yamaguchi University with the network established by Nozomi MedAlliance, the partnership will devise commercialization strategies to ensure seamless access to international markets.
  • 　
Contact
  • ＜Research Inquiries＞
  • Kazuki Hamada, M.D., Ph.D.
  • Assistant Professor, Department of Respiratory Medicine and Infectious Diseases, Yamaguchi University Hospital
  • TEL: 0836-85-3123
  • E-mail: khamada@（followed by yamaguchi-u.ac.jp）
  • 　　
  • ＜Regarding public relations＞
  • Yamaguchi University Research Institute for Cell Design Medical Science (Life Science Support Section, Academic Research Division)
  • TEL: 0836-85-3065
  • E-mail: sh088@ ( followed by yamaguchi-u.ac.jp)

Back